The drug for the treatment of coronavirus “Mir-19” completes the second phase of clinical trials -practical conference “Molecular Diagnostics – 2021”, TASS reports.
She recalled that Mir-19 belongs to the group of etiotropic antiviral drugs. It is intended for the prevention or treatment of COVID-19 through inhalation or intranasal administration.
Skvortsova assured that the drug is safe and does not affect the human genome and immunity. At the same time, Mir-19 prevents the most severe forms of the development of coronavirus.
Earlier, Russia created its own drug for coronavirus, Innoviron, developed by Valenta Pharm. Experts conducted the second phase of drug testing back in June. At the end of October this year, documents were sent to register the development.